Linking GWAS risk variants to disease genes by epigenomic mapping and prediction of functional enhancer-promoter interactions

Camp4 Therapeutics Corporation published this content on October 26, 2022, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on October 02, 2025 at 08:18 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]